PRIME THERAPEUTICS for PRIME THERAPEUTICS
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
S. 778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Health Issues HCR
HR 749: Lower Drug Costs Through Competition Act - increasing generic competition. Legislation to address abuses of the REMS program to allow generic drugs to come to market faster. Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. HR 1121: Preexisting Conditions Protect Act of 2017 - issues relating to market stability in exchanges. S. 191: Patient Freedom Act of 2017 - issues relating to market stability in exchanges. S. 469/H.R. 1245: Affordable and Safe Prescription Drug Importation Act. H.R. 1316: The Prescription Drug Price Transparency Act - issues relating to ensuring continued use of MAC pricing. S. 771/H.R. 1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. H.R. 1628: The American Health Care Act of 2017 - issues related to market stabilization. S.778: Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Medicare/Medicaid MMM
S.413/H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act - restrictions on payor quallity programs in Medicare Part D. Draft bill to amend title XVIII of the Social Security Act to provide for greater access to drug cost information for Medicare beneficiaries by preventing cash price disclosure restrictions under Medicare prescription drug plan contracts with pharmacies - issues related to noninterference in Medicare Part D. Counter efforts to elimination of the Medicare Part D non-interference clause. H.R. 1316: The Prescription Drug Price Transparency Act - issues relating to ensuring continued use of MAC pricing. S. 637: Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act - Issues relating to Medicare Part D cash price disclosure. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. Draft bill to amend part A of title XVIII of the Social Security Act to provide greater access to information regarding the items and services furnished to the individual under parts A and B of the Medicare program and greater context regarding the medication regimen of the individual - issues relating to use of Medicare data.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Pharmacy PHA
Generic drug user fee act - provisions to ensure greater market competition for generics. Biosimilar drug user fee act - ensuring greater competition in the biosimilar market. S.469/H.R.1245: Affordable and Safe Prescription Drug Importation Act. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act - issues relating to ensuring a competitive drug marketplace. S.778:Prescription Drug Monitoring Act - issues related to dispensers access to PDMPs across state lines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIE CAROL CANTOR-WEINBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.